B-cell depletion improves therapeutic index of combination checkpoint blockade in patients with advanced melanoma
In brief
Rituximab cuts severe checkpoint-therapy side effects from 57% to 14% in melanoma
In a small randomized trial of 14 patients with advanced melanoma, adding one cycle of rituximab to ipilimumab-nivolumab lowered grade-3 immune-related adverse events to 14% and raised two-year severe-AE-free survival to 86% without harming tumor response or overall survival. However, high rates of rituximab-related hypersensitivity (43%) halted the study, leaving safety of the combination unresolved.
- Journal
- The Journal of clinical investigation (Q1)
- Published
- 25 August 2026
- Study design
- Randomized controlled trial
- Evidence level
- Level 1, High (CEBM 1b)
- Authors
- Kavita M Dhodapkar, Antonio Matera, Alyssa M Duffy, Azmain Taz, Renee Julia Manalo, Melinda Yushak, et al.
- PMID
- 42640721
- DOI
- 10.1172/JCI205606
Why clinicians should know about it
- Picked for Dermatology (top studies of the week, 30 August 2026): B‑cell depletion reduces irAEs in melanoma checkpoint therapy
- Picked for Oncology and Radiation Oncology (top studies of the week, 30 August 2026): B‑cell depletion reduces checkpoint‑blockade irAEs
Abstract
BACKGROUND: Combined checkpoint blockade (CCB) of programmed-death-1 (PD-1) and cytotoxic-T-lymphocyte-associated protein-4 (CTLA-4) is highly active in melanoma but limited by significant morbidity from immune-related adverse events (irAEs). Effective strategies to prevent CCB-mediated irAEs are lacking. METHODS: Patients with advanced melanoma were randomly assigned to receive standard of care ipilimumab and nivolumab alone (Arm-A: ipi/nivo, n=7) or with one cycle of rituximab (Arm-B; ipi/nivo+rituximab, n=7). RESULTS: Patients receiving ipi/nivo+rituximab experienced lower rates of > grade-3(G3) irAEs (14% versus 57%) and superior G3-irAE-free survival compared to those in ipi/nivo arm (2-year G3-irAE-free survival 86% versus 29% (p=0.01), without adverse impact on tumor regression or survival. G3 hypersensitivity reactions to rituximab (43% in Arm-B) prompted trial closure. Rituximab depleted pre-therapy activated naïve B cells linked to autoimmunity and enhanced CCB-mediated induction of myeloid inflammation and CXCL13+ICOS+ CD4 T cells. CONCLUSION: B-cell depletion favorably modulates CCB-mediated immune activation and may reduce irAE risk. TRIAL REGISTRATION: ClinicalTrials.gov NCT03719131 Funding: NIH.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.